Us Point Of Care Molecular Diagnostics Market Report: Market Size & Forecast 2026

The market covers molecular diagnostic products and services that deliver nucleic acid-based testing results rapidly at or near the site of patient care, bypassing the throughput and turnaround-time constraints of central reference laboratories. Core applications span infectious disease panels (respiratory pathogens, sexually transmitted infections, hospital-acquired infections), genetic and genomic screening, oncology companion diagnostics, and antimicrobial resistance detection. Revenue growth is supported by recurring consumable sales (cartridges, reagents, swabs) alongside instrument placement and service contracts.

• •The North America molecular diagnostics market reached approximately $11.52 billion in 2025 and is projected to reach roughly $15.87 billion by 2030
• •The United States represents the dominant country-level market within North America and is expected to maintain that position through the forecast horizon
• •Sample-to-answer cartridge platforms that minimize operator steps are increasingly replacing traditional benchtop lab instruments in near-patient settings

The demand for results within a clinical visit or even at home is the primary structural force reshaping testing workflows, as healthcare systems prioritize reduced patient wait times and earlier therapeutic decisions. Pandemic-era investments expanded molecular testing infrastructure into non-traditional settings, and that installed base continues to support utilization growth across both acute and routine testing. An aging demographic profile and rising prevalence of chronic and infectious diseases in North America further sustain upward demand trajectories.

• •Decentralization of care delivery and the proliferation of urgent-care and retail-health sites require testing solutions that operate outside complex laboratory environments
• •Regulatory expansion of CLIA-waived and over-the-counter molecular test authorizations broadens the eligible user base and deployment locations
• •Antimicrobial resistance surveillance and the need for rapid pathogen identification in hospital and long-term-care settings drive institutional adoption

The market spans multiple product and application categories, with infectious disease testing representing the largest segment by revenue, followed by genetic disease and oncology-related applications. By technology, the market includes isothermal amplification, real-time PCR, and emerging CRISPR-based and next-generation sequencing methods, each serving different throughput and complexity requirements. Geographically, the United States commands the preponderance of North American market share, supported by advanced healthcare infrastructure, favorable reimbursement frameworks, and higher per-capita health spending relative to Canada and Mexico.

• •Infectious disease panels, particularly respiratory and sexually transmitted infection testing, represent the single largest application category in the market
• •Genetic sequencing-based point-of-care approaches are gaining share as sequencing costs decline and compact sequencers become commercially viable for near-patient use
• •The U.S. market is forecast to reach approximately $1.1 billion in value within the North American POC molecular segment by 2030, reflecting its outsized regional contribution

Who are the notable companies in the industry?

The market features a combination of large, diversified life-science corporations that operate integrated diagnostic portfolios spanning reagents, instruments, and software, alongside mid-tier specialty producers that concentrate exclusively on molecular diagnostics platforms. Production and technology development rely on several distinct process routes, including isothermal amplification chemistries, real-time quantitative PCR, microfluidic cartridge engineering, and, increasingly, CRISPR-guided detection systems. Manufacturing and R&D capacity are concentrated primarily in the United States, with notable secondary hubs in Canada and Mexico, reflecting regional talent pools, regulatory proximity, and established supply-chain ecosystems.

• •The competitive structure ranges from vertically integrated producers offering full diagnostic ecosystems to focused specialty manufacturers targeting specific molecular platform technologies
• •Key technology and process routes include nucleic acid amplification tests, microfluidic-based sample processing, and emerging CRISPR and sequencing-miniaturization platforms
• •Production capacity and R&D investment are concentrated in the United States, followed by Canada, with Mexico playing a growing manufacturing and assembly role

What are the recent trends and outlook?

Product development is increasingly oriented toward fully integrated, truly portable devices that deliver laboratory-quality results with minimal training, enabling deployment in pharmacies, ambulances, long-term-care facilities, and private homes. Connectivity features embedded in testing devices are enabling real-time data transmission to electronic health records and public health surveillance systems, adding value beyond the test result itself. As reimbursement policies evolve and regulatory pathways mature, the addressable market for at-home and over-the-counter molecular testing is expected to expand significantly.

• •Multiplex panels capable of detecting multiple pathogens or biomarkers from a single sample are becoming a primary differentiation axis among manufacturers
• •Artificial intelligence integration for result interpretation and quality control is emerging as a feature premium in next-generation platform designs
• •Telehealth expansion and direct-to-consumer distribution channels are creating new routes to market beyond traditional institutional sales